ZEO ScientifiX net loss narrows to $1 million for six months ended April 30, FY26; revenue rises 79.9% to $4.03 million

ZEO ScientifiX reported a narrowed net loss of $1 million for the six months ended April 30, FY26, down from $2.6 million previously. Revenue surged 79.9% year-over-year to $4.03 million, with Q2 revenue doubling to $2.58 million. Gross margins remained stable at approximately 80%, driven by higher allogenic biologic product sales. CEO Ian Bothwell cited an 'inflection point' due to increased physician adoption and strong demand in Florida.

ZEO ScientifiX posted revenue of $2.58 million for the three months ended April 30, 2026, more than doubled from a year earlier (+124.6%). * Six-month revenue climbed to $4.03 million, up 79.9% year over year. * Net loss narrowed to about $1 million for the six months, from about $2.6 million a year earlier. * Gross margin held at about 80% for the six-month period; results reflected higher allogenic biologic product revenue. * CEO Ian Bothwell said the period marked an “inflection point,” citing rising physician adoption and stronger demand in Florida for stem-cell-focused products. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ZEO Scientifix Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607080700ACCESSWRNAPR_____1187693) on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

ZEO ScientifiX posted revenue of $2.58 million for the three months ended April 30, 2026, more than doubled from a year earlier (+124.6%). * Six-month revenue climbed to $4.03 million, up 79.9% year over year. * Net loss narrowed to about $1 million for the six months, from about $2.6 million a year earlier. * Gross margin held at about 80% for the six-month period; results reflected higher allogenic biologic product revenue. * CEO Ian Bothwell said the period marked an “inflection point,” citing rising physician adoption and stronger demand in Florida for stem-cell-focused products. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ZEO Scientifix Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607080700ACCESSWRNAPR_____1187693) on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)